The drug’s mechanism is to recruit the cell’s own disposal system to eliminate disease‑causing proteins.
It received official approval from the United States Food and Drug Administration, allowing it to be used in patients.
The therapy targets cancers that were difficult to treat with traditional medicines.
Researchers have spent over twenty years developing PROteolysis Targeting Chimera technology.
The approval marks a major shift toward protein‑removing treatments rather than blocking them.
Patients may soon have an additional option for cancer therapy.
This approach, known as PROteolysis Targeting Chimera, works by tagging unwanted proteins for destruction.
It provides a fresh way to treat cancers that involve proteins previously considered “undruggable.”
The breakthrough follows more than two decades of research into this technology.
Want to learn even more? Click here to read the full story!